$BAX (Baxter International Inc.)

$BAX {{ '2016-07-26T11:47:47+0000' | timeago}} • Announcement

$BAX, which develops products that treat hemophilia, kidney disease immune disorders, said it expects 3Q16 adjusted EPS from continuing operations of $0.43-0.45. The company expects sales growth of 2-3% on reported basis and 3-4% on constant currency basis. $BAX anticipates GAAP EPS of $0.25-0.29.

$BAX {{ '2017-10-12T20:41:03+0000' | timeago}} • Announcement

$BAX provided updates regarding recovery efforts following the impact of Hurricane Maria on its Puerto Rico operations. While $BAX now anticipates a reduction in revenue for 4Q17 as a result of the storm, the company expects to mitigate the related earnings impact through positive performance in other areas of the business.

$BAX {{ '2017-10-03T14:37:28+0000' | timeago}} • Announcement

$BAX announced enrollment of first patients in two new clinical trials for a unique expanded hemodialysis (HDx) therapy enabled by Theranova. Baxter’s HDx therapy enabled by Theranova was designed to remove large molecular weight toxins that have been associated with inflammation and cardiovascular health for end-stage renal disease patients.

$BAX {{ '2017-08-31T13:27:20+0000' | timeago}} • Announcement

$BAX and MATTER announced a new collaboration to drive forward innovation focused on improving the value and quality of healthcare. This new partnership builds on $BAX's recently announced research collaborations with Mayo Clinic, Tel Aviv University and Tel Aviv Sourasky Medical Center.

$BAX {{ '2017-07-27T13:25:22+0000' | timeago}} • Announcement

Healthcare products provider $BAX has completed the acquisition of pharmaceutical company Claris Injectables. The $625MM transaction was financed through a combination of cash and debt. The company expects the acquisition to be modestly accretive to its adjusted earnings in 2017, and increasingly accretive thereafter.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

$BAX {{ '2017-07-26T12:52:56+0000' | timeago}} • Announcement

$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.

$BAX {{ '2017-07-26T12:46:39+0000' | timeago}} • Announcement

$BAX's renal sales totaled $968MM, comparable to the prior year on reported basis and up 3% on both a constant currency basis and operational basis. Growth was driven by increased sales for in-center hemodialysis (HD) products in the US, international acute renal care sales and global sales of peritoneal dialysis (PD) therapies.

$BAX {{ '2017-07-26T12:45:36+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 2Q17, rising 1% on reported, 2% on constant currency and 4% operationally. This was driven by continued strength in US fluid systems business, favorable demand for parenteral nutrition therapies and pre-mixed injectable, as well as for select anesthesia and critical care products.

$BAX {{ '2017-07-26T12:42:25+0000' | timeago}} • Announcement

$BAX reported a 78% dip in 2Q17 earnings due to last year's net realized gains from exchange of its retained shares of Baxalta and contribution to its U.S. pension fund. Net income dropped to $265MM or $0.48 per share from $1.21Bil or $2.19 per share last year. Net sales rose 1% to $2.61Bil. Adjusted EPS grew 37% to $0.63.

$BAX {{ '2017-07-18T14:01:55+0000' | timeago}} • Announcement

The BoD of $BAX declared a quarterly dividend of $0.16 per share of its common stock. The dividend is payable on Oct 2, 2017, to stockholders of record as of Sept 1, 2017.

$BAX {{ '2017-07-17T20:58:53+0000' | timeago}} • Announcement

$BAX appointed Cathy Smith, EVP and CFO of $TGT, to its BoD, bringing the total number of directors serving the company at this time to 13. Smith now also serves on $BAX's Audit Committee.

$BAX {{ '2017-06-26T13:13:55+0000' | timeago}} • Announcement

$BAX has announced a bi-directional integration between its software solution DoseEdge Pharmacy Workflow Manager and the Epic Willow Inpatient Pharmacy System. The integration will help hospitals efficiently comply with requirements from the Centers for Medicare and Medicaid Services and other insurers.

$BAX {{ '2017-06-14T12:53:57+0000' | timeago}} • Announcement

$BAX recently announced plans to expand its presence in the space with the pending acquisition of Claris Injectables. The acquisition of Claris is expected to close in 2H17. $BAX recently announced a strategic partnership with ScinoPharm to develop, manufacture and commercialize five generic injectables used in cancer treatment.

$BAX {{ '2017-06-14T12:50:42+0000' | timeago}} • Announcement

$BAX agreed with Dorizoe Lifesciences to facilitate accelerated development of more than 20 generic injectable products, including anti-infectives, oncolytics and cardiovascular medicines. Dorizoe will work with $BAX to perform certain product development activities, and $BAX will hold worldwide manufacturing and commercialization rights.

$BAX {{ '2017-06-07T15:22:17+0000' | timeago}} • Announcement

$BAX announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations. Clindamycin is used to treat serious infections caused by bacteria.

$BAX {{ '2017-06-05T20:30:19+0000' | timeago}} • Announcement

$BAX presented new data demonstrating abilities of its Sharesource remote patient management technology to improve the care of peritoneal dialysis patients and increase dialysis clinic efficiencies. The cloud-based platform offers healthcare providers more accurate and timely visibility to patients’ therapy adherence, allowing timely intervention.

$BAX {{ '2017-06-05T13:03:56+0000' | timeago}} • Announcement

$BAX said data from two independent studies concluded that HDx, or expanded hemodialysis therapy, enabled by the Theranova dialyzer effectively removed small and mid-sized toxins at similar rates when compared to hemodiafiltration (HDF), another type of dialysis.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
ATHX (Athersys, Inc.)
Wednesday, August 9 2017 - 8:30pm
VCEL (Vericel Corporation)
Wednesday, August 9 2017 - 12:00pm
OPK (Opko Health, Inc.)
Tuesday, August 8 2017 - 8:30pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
ABC (AmerisourceBergen Corporation)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, August 3 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, August 2 2017 - 9:30pm
ITRI (Itron, Inc.)
Wednesday, August 2 2017 - 9:00pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, August 2 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm

AlphaGraphics you may like